Sustained immunological memory to SARS-CoV-2 antigens. Three years of observation
The COVID-19 pandemic has ended, but SARS-CoV-2 continues to actively circulate and mutate in the human population. In this regard, it is important to understand for how long post-infectious and post-vaccination immunity may last and how effectively established immunity could act against new mutant...
Saved in:
Published in | Infekt͡s︡ii͡a︡ i immunitet Vol. 14; no. 1; pp. 35 - 45 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
28.04.2024
|
Online Access | Get full text |
Cover
Loading…
Abstract | The COVID-19 pandemic has ended, but SARS-CoV-2 continues to actively circulate and mutate in the human population. In this regard, it is important to understand for how long post-infectious and post-vaccination immunity may last and how effectively established immunity could act against new mutant SARS-CoV-2 strains. The aim was to study humoral and cellular immunity in a group of COVID-19 convalescent subjects within 3 years after the primary infection. The longitudinal study included 38 adults aged 23–72 years with PCR-confirmed mild or moderate COVID-19 in the second half of 2020. Within three-year follow-up after the onset, the subjects were examined every 6 months for the level of humoral and cellular immunity against SARS-CoV-2 antigens. The parameters of humoral immunity were assessed by enzyme immunoassay using “SARS-CoV-2-IgG quantitative-ELISA-BEST” kits (Vector-Best JSC, Novosibirsk, Russian Federation) for S-protein and “N-CoV-2-IgG PS” (Saint-Petersburg Pasteur Institute, St. Petersburg, Russian Federation) specific to the N-protein. Cellular anti-SARS-CoV-2 immunity was analyzed by evaluating surface CD107a expression on CD8high lymphocytes stimulated with the SARS-CoV-2 S- or N-antigens. It was shown that the dynamics of antibody levels against SARS-COV-2 antigens depends on antigen (S- or N-protein) type, antibody class (IgG or IgA) as well as individual contact history with new SARS-CoV-2 strains. The dynamics of cytotoxic CD8highCD107a+ lymphocyte percentage is moderately positively correlated with that of the corresponding anti-S or N antibody levels. At the same time, change in the levels of both humoral and T-cell responses to SARS-CoV-2 S- or N-protein antigens are weakly negatively correlated with each other. A strong positive correlation was found between changes in the anti-S IgG antibody level and avidity. Avoiding the anti-S IgG neutralization due to frequent mutations of new SARS-CoV-2 strains leads to induced new primary immune responses against SARS-CoV-2 antigens along with the activation of existing responses formed to previous coronavirus strains. The study of immune responses against SARS-CoV-2 antigens allows to predict the persistence of high SARS-CoV-2 anti-S antibody and T-cell response levels. |
---|---|
AbstractList | The COVID-19 pandemic has ended, but SARS-CoV-2 continues to actively circulate and mutate in the human population. In this regard, it is important to understand for how long post-infectious and post-vaccination immunity may last and how effectively established immunity could act against new mutant SARS-CoV-2 strains. The aim was to study humoral and cellular immunity in a group of COVID-19 convalescent subjects within 3 years after the primary infection. The longitudinal study included 38 adults aged 23–72 years with PCR-confirmed mild or moderate COVID-19 in the second half of 2020. Within three-year follow-up after the onset, the subjects were examined every 6 months for the level of humoral and cellular immunity against SARS-CoV-2 antigens. The parameters of humoral immunity were assessed by enzyme immunoassay using “SARS-CoV-2-IgG quantitative-ELISA-BEST” kits (Vector-Best JSC, Novosibirsk, Russian Federation) for S-protein and “N-CoV-2-IgG PS” (Saint-Petersburg Pasteur Institute, St. Petersburg, Russian Federation) specific to the N-protein. Cellular anti-SARS-CoV-2 immunity was analyzed by evaluating surface CD107a expression on CD8high lymphocytes stimulated with the SARS-CoV-2 S- or N-antigens. It was shown that the dynamics of antibody levels against SARS-COV-2 antigens depends on antigen (S- or N-protein) type, antibody class (IgG or IgA) as well as individual contact history with new SARS-CoV-2 strains. The dynamics of cytotoxic CD8highCD107a+ lymphocyte percentage is moderately positively correlated with that of the corresponding anti-S or N antibody levels. At the same time, change in the levels of both humoral and T-cell responses to SARS-CoV-2 S- or N-protein antigens are weakly negatively correlated with each other. A strong positive correlation was found between changes in the anti-S IgG antibody level and avidity. Avoiding the anti-S IgG neutralization due to frequent mutations of new SARS-CoV-2 strains leads to induced new primary immune responses against SARS-CoV-2 antigens along with the activation of existing responses formed to previous coronavirus strains. The study of immune responses against SARS-CoV-2 antigens allows to predict the persistence of high SARS-CoV-2 anti-S antibody and T-cell response levels. |
Author | Afridonova, Z. E. Toptygina, A. P. Semikina, E. L. |
Author_xml | – sequence: 1 givenname: Z. E. surname: Afridonova fullname: Afridonova, Z. E. – sequence: 2 givenname: A. P. surname: Toptygina fullname: Toptygina, A. P. – sequence: 3 givenname: E. L. surname: Semikina fullname: Semikina, E. L. |
BookMark | eNo1kMtOwzAURC1UJErpH7DwD7jY10kcL6uKR6UiBClsLSe5LkGNjewUqX_fB7CaWYxGOueajHzwSMit4DORq1LfAQBnqhCaVctnJlSuiwsyBikkU1KXo2P_X1yRaUpfnHOhALQsxuS12qXBdh5b2vX9zodt2HSN3dIe-xD3dAi0mr9VbBE-GFDrh26DPs3o-jMi0j3amGhwNNQJ448duuBvyKWz24TTv5yQ94f79eKJrV4el4v5ijVCFQOTDtBCawsoS2hRNa5EIZWrwTWgM1e3WqvC5bkGbmt3BBUZb7FUbaZ5rYWckOz3t4khpYjOfMeut3FvBDdnM-bEbU7c5mjGnM3IA3LIWO4 |
Cites_doi | 10.3390/v14050941 10.1016/S2666-7568(21)00282-8 10.1016/S0140-6736(21)01642-1 10.1038/s41586-020-2548-6 10.1038/s41590-020-00814-z 10.4049/jimmunol.174.8.4718 10.15789/2220-7619-AOF-2107 10.1134/S0006297924050080 10.1001/jama.2022.1393 10.1038/s41598-021-95045-z 10.1016/j.immuni.2020.07.005 10.4049/jimmunol.2100135 10.1126/sciimmunol.abd7114 10.3233/HAB-210440 10.15789/2220-7619-CAN-1904 10.3389/fimmu.2021.647934 10.3389/fimmu.2023.1133225 10.1038/s41467-021-27674-x 10.3390/vaccines10071143 10.1038/s41586-021-03696-9 10.1056/NEJMoa2109072 10.1172/JCI142004 10.1038/s41467-023-36250-4 10.1126/sciimmunol.ade2798 10.1128/jvi.00760-22 10.1016/j.chom.2020.09.002 10.1126/sciimmunol.abg6916 10.15789/2220-7619-COT-1809 10.1126/sciimmunol.abj1750 10.1038/s41591-021-01377-8 10.15789/2220-7619-MIM-2009 10.3390/biom13091338 10.1016/j.ejim.2021.09.012 |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.15789/2220-7619-SIM-17596 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2313-7398 |
EndPage | 45 |
ExternalDocumentID | 10_15789_2220_7619_SIM_17596 |
GroupedDBID | 642 AAYXX ADBBV ALMA_UNASSIGNED_HOLDINGS BCNDV CITATION GROUPED_DOAJ KQ8 |
ID | FETCH-LOGICAL-c176t-3f2ea2da62882de7cf8e137fb2fc294fbd9976f55920abf789140de87d490b913 |
ISSN | 2220-7619 |
IngestDate | Tue Jul 01 00:41:21 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c176t-3f2ea2da62882de7cf8e137fb2fc294fbd9976f55920abf789140de87d490b913 |
OpenAccessLink | https://iimmun.ru/iimm/article/download/17596/1939 |
PageCount | 11 |
ParticipantIDs | crossref_primary_10_15789_2220_7619_SIM_17596 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-04-28 |
PublicationDateYYYYMMDD | 2024-04-28 |
PublicationDate_xml | – month: 04 year: 2024 text: 2024-04-28 day: 28 |
PublicationDecade | 2020 |
PublicationTitle | Infekt͡s︡ii͡a︡ i immunitet |
PublicationYear | 2024 |
References | ref13 ref12 ref15 ref14 ref31 ref30 ref11 ref33 ref10 ref32 ref2 ref1 ref17 ref16 ref19 ref18 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref28 ref27 ref29 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
References_xml | – ident: ref14 doi: 10.3390/v14050941 – ident: ref15 doi: 10.1016/S2666-7568(21)00282-8 – ident: ref30 doi: 10.1016/S0140-6736(21)01642-1 – ident: ref33 doi: 10.1038/s41586-020-2548-6 – ident: ref32 doi: 10.1038/s41590-020-00814-z – ident: ref29 doi: 10.4049/jimmunol.174.8.4718 – ident: ref3 doi: 10.15789/2220-7619-AOF-2107 – ident: ref1 doi: 10.1134/S0006297924050080 – ident: ref6 doi: 10.1001/jama.2022.1393 – ident: ref19 doi: 10.1038/s41598-021-95045-z – ident: ref28 doi: 10.1016/j.immuni.2020.07.005 – ident: ref10 doi: 10.4049/jimmunol.2100135 – ident: ref17 doi: 10.1126/sciimmunol.abd7114 – ident: ref25 doi: 10.3233/HAB-210440 – ident: ref2 doi: 10.15789/2220-7619-CAN-1904 – ident: ref21 doi: 10.3389/fimmu.2021.647934 – ident: ref22 doi: 10.3389/fimmu.2023.1133225 – ident: ref16 doi: 10.1038/s41467-021-27674-x – ident: ref18 doi: 10.3390/vaccines10071143 – ident: ref31 doi: 10.1038/s41586-021-03696-9 – ident: ref7 doi: 10.1056/NEJMoa2109072 – ident: ref13 doi: 10.1172/JCI142004 – ident: ref24 doi: 10.1038/s41467-023-36250-4 – ident: ref11 doi: 10.1126/sciimmunol.ade2798 – ident: ref23 doi: 10.1128/jvi.00760-22 – ident: ref20 doi: 10.1016/j.chom.2020.09.002 – ident: ref27 doi: 10.1126/sciimmunol.abg6916 – ident: ref5 doi: 10.15789/2220-7619-COT-1809 – ident: ref9 doi: 10.1126/sciimmunol.abj1750 – ident: ref12 doi: 10.1038/s41591-021-01377-8 – ident: ref4 doi: 10.15789/2220-7619-MIM-2009 – ident: ref26 doi: 10.3390/biom13091338 – ident: ref8 doi: 10.1016/j.ejim.2021.09.012 |
SSID | ssj0001722936 ssib046627272 ssib044739665 |
Score | 2.2544737 |
Snippet | The COVID-19 pandemic has ended, but SARS-CoV-2 continues to actively circulate and mutate in the human population. In this regard, it is important to... |
SourceID | crossref |
SourceType | Index Database |
StartPage | 35 |
Title | Sustained immunological memory to SARS-CoV-2 antigens. Three years of observation |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKEBIvaHyJMYb8QJ8ih8bO4vixK502xBCQDu0tshNbiqY105Y9lD-Dv5iznbmBVYjxEkWX5pzkfjrfXe8DoXeZkVxKs0-kqGqSKs2JyitKpMplpZjJjbEFziefs6PT9OPZ_tlo9HOQtXTTqbj6sbGu5H-kCjSQq62SvYdkA1MgwDnIF44gYTj-k4wLX_0ENmNjyzyCHruw6bPOrCym3woya78TGsEntJ03r-NoAfLT0Qow7vI4WhUis0NT9Xhp9Hk3nn0YT5Pr8fxwfJDDWdN4igyUqPGrg-0aUmjs9KG6tfNW3Z8fcTSP1-Hsy25lh0E4rRRHX8KVQl805_2FeRx9iocRCeoSWehAiYLJMSE2POL3GE9jCSOc-YnTQfOmdxDm1ajvYNJvyL7d5B1VD6rGtkoNi5Hi-ISAMSQ2dNb-Y8cLeYjWA7J8SsultFxK4FI6Lg_QQwquBx246aCj0hReYtAiMLUN9Glfe-zienCLcJMpw5P1FZt2ofcbHndgEQ1Mm8U2etL7JHjqAfYUjfTyGXrkp5SunqOvAWb4N5hhDzPctXgNMxxghh3MsIMZbg0ewOwFOj2cL2ZHpJ_EQaqEZx1hhmpJa2lnU9Na88rkOmHcKGoqKlKjagFmrQHvlE6kMvCi4LfXOud1KiZKJOwl2lq2S_0KYaYFn-iamUSYNKsyuDWXlFZcMiqZMTuI3H6N8tI3XCn_JqbX9_z9Lnq8xuwbtNVd3eg9sCs79dYJ-hecOWwr |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sustained+immunological+memory+to+SARS-CoV-2+antigens.+Three+years+of+observation&rft.jtitle=Infekt%CD%A1s%EF%B8%A1ii%CD%A1a%EF%B8%A1+i+immunitet&rft.au=Afridonova%2C+Z.+E.&rft.au=Toptygina%2C+A.+P.&rft.au=Semikina%2C+E.+L.&rft.date=2024-04-28&rft.issn=2220-7619&rft.eissn=2313-7398&rft.volume=14&rft.issue=1&rft.spage=35&rft.epage=45&rft_id=info:doi/10.15789%2F2220-7619-SIM-17596&rft.externalDBID=n%2Fa&rft.externalDocID=10_15789_2220_7619_SIM_17596 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2220-7619&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2220-7619&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2220-7619&client=summon |